These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 8970537)

  • 61. [Iodine-131 therapy of autonomous adenoma of the thyroid. 7-year results].
    Heinze HG; Bohn U
    Dtsch Med Wochenschr; 1987 Jul; 112(27):1073-9. PubMed ID: 3595467
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Radioiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity.
    Clerc J; Dagousset F; Izembart M; Jais JP; Heshmati HM; Alcaïs A; Chevalier A; Léger AF; Barritault L
    J Nucl Med; 1995 Feb; 36(2):217-23. PubMed ID: 7830117
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy.
    Fast S; Hegedüs L; Grupe P; Nielsen VE; Bluhme C; Bastholt L; Bonnema SJ
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3719-25. PubMed ID: 20519346
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
    Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
    Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Use of 131 iodine for the treatment of hyperthyroidism in adults].
    Glinoer D; Verelst J
    Ann Endocrinol (Paris); 1996; 57(3):177-85. PubMed ID: 8949412
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Radioiodine therapy of funcitonal autonomy using the functional autonomous volume].
    Seeger T; Emrich D; Sandrock D
    Nuklearmedizin; 1995 Aug; 34(4):135-40. PubMed ID: 7675642
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.
    Canzi C; Zito F; Voltini F; Reschini E; Gerundini P
    Med Phys; 2006 Aug; 33(8):2860-7. PubMed ID: 16964862
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Reduction of thyroid volume following radioiodine therapy for functional autonomy].
    Luster M; Jacob M; Thelen MH; Michalowski U; Deutsch U; Reiners C
    Nuklearmedizin; 1995 Apr; 34(2):57-60. PubMed ID: 7761274
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Radioiodine therapy for multinodular toxic goiter.
    Nygaard B; Hegedüs L; Ulriksen P; Nielsen KG; Hansen JM
    Arch Intern Med; 1999 Jun; 159(12):1364-8. PubMed ID: 10386513
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters.
    Braverman L; Kloos RT; Law B; Kipnes M; Dionne M; Magner J
    Endocr Pract; 2008 Oct; 14(7):832-9. PubMed ID: 18996810
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Radioiodine therapy increases the risk of cerebrovascular events in hyperthyroid and euthyroid patients.
    la Cour JL; Jensen LT; Vej-Hansen A; Nygaard B
    Eur J Endocrinol; 2015 Jun; 172(6):771-8. PubMed ID: 25920711
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [The treatment of multinodular large non-toxic goiter using repeated doses of radioiodine (preliminary report)].
    Pisarek M; Baczyk M; Gryczyńska M; Sowiński J
    Endokrynol Pol; 2007; 58(1):18-26. PubMed ID: 17354201
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Therapeutic results in hyperthyroid patients from the Bern endemic goiter region].
    Fischer H; Morgenthaler B; König MP
    Schweiz Med Wochenschr; 1984 Apr; 114(16):550-6. PubMed ID: 6474118
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
    Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
    Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not.
    Krohn T; Hänscheid H; Müller B; Behrendt FF; Heinzel A; Mottaghy FM; Verburg FA
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4109-15. PubMed ID: 25033065
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Reduced radiation sensitivity of hyperthyroid goiter with endocrine ophthalmopathy (author's transl)].
    Mertz DP; Koch B
    MMW Munch Med Wochenschr; 1977 Jul; 119(28):945-8. PubMed ID: 408626
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
    Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
    Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial.
    Nielsen VE; Bonnema SJ; Boel-Jørgensen H; Veje A; Hegedüs L
    J Clin Endocrinol Metab; 2005 Jan; 90(1):79-83. PubMed ID: 15494456
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Radioiodine treatment of multinodular non-toxic goitre.
    Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Søe-Jensen P; Hansen JM
    BMJ; 1993 Oct; 307(6908):828-32. PubMed ID: 8401123
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Discrepant salivary gland response after radioiodine and MIBG therapies.
    Jentzen W; Richter M; Poeppel TD; Schmitz J; Brandau W; Bockisch A; Binse I
    Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):331-339. PubMed ID: 25566809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.